SAVANNAH and ORCHARD Phase II trials show the addition of savolitinib or datopotamab deruxtecan-dlnk to TAGRISSO upon disease progression demonstrates strong clinical activity Susan Galbraith, ...

Cretostimogene demonstrated HG-EFS at 3- 6- and 9-months of 95.7%, 84.6% and 80.4%, respectively, in HR BCG UR Ta/T1 Disease in BOND-003 Cohort P CORE-008 Cohort A Data in HR BCG-Naïve NMIBC ...

Dr. Suresh Ramalingam discussed how the LAURA findings support the role of Tagrisso as a backbone therapy across multiple settings in EGFR-mutated NSCLC. The phase 3 LAURA trial showed that treatment ...

Phase 2 study showed a doubling of the survival rate of metastatic pancreatic cancer patients at Year 1, an unprecedented outcome Technology is seen as transformative in increasing the effectiveness ...

In this open-label trial with a 2-by-4 factorial design, we randomly assigned children with HIV who had first-line treatment failure to receive second-line therapy with tenofovir alafenamide fumarate ...

NEW YORK, March 20, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that ...

Vexing challenges await cancer researchers every day — not just in finding new molecules — but now, increasingly, in finding new ways to make tumors more vulnerable to existing drugs. Tumors have ...

CHICAGO, IL AND FORT WORTH, TX / ACCESS Newswire / August 25, 2025 / Vexing challenges await cancer researchers every day -- not just in finding new molecules -- but now, increasingly, in finding new ...

SAN FRANCISCO and SUZHOU, China, Oct. 21, 2025 /PRNewswire/ -- Innovent Biologics (HKEX: 01801) announced a strategic global collaboration with Takeda (TSE:4502, NYSE:TAK) to advance next-generation ...